
|Videos|July 31, 2020
ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO
Author(s)Alex Delaney-Gesing
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















